Towards systematic functional characterization of cancer genomes

Nature Reviews Genetics

Volumn 12, Issue 7, 2011, Pages 487-498

  Boehm, Jesse S ^a   Hahn, William C ^a,b,c  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MICRORNA;

FUNCTIONAL GENOMICS; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENOME; HUMAN; MUTAGENESIS; NEOPLASM; ONCOGENE; OPEN READING FRAME; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS;

ALGORITHMS; ANIMALS; DATABASES, GENETIC; GENOME, HUMAN; GENOMICS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RESEARCH DESIGN;

EID: 79959480919     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3013     Document Type: Review

References (113)

1. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nature Rev. Genet. 11, 685-696 (2010).
2. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
3. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002). (Pubitemid 35461656)
4. McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumours to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389-3395 (2008).
5. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
6. Copeland, N. G. & Jenkins, N. A. Harnessing transposons for cancer gene discovery. Nature Rev. Cancer 10, 696-706 (2010).
7. Starr, T. K. et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323, 1747-1750 (2009).
8. Ding, S. et al. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122, 473-483 (2005). (Pubitemid 41127147)
9. Rad, R. et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 330, 1104-1107 (2010).
10. Sun, L. V. et al. PBmice: an integrated database system of piggyBac (PB) insertional mutations and their characterizations in mice. Nucleic Acids Res. 36, D729-D734 (2008). (Pubitemid 351149815)
11. Kool, J. & Berns, A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nature Rev. Cancer 9, 389-399 (2009).
12. Uren, A. G. et al. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 133, 727-741 (2008). (Pubitemid 351637624)
13. Carette, J. E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235 (2009).
14. MacKeigan, J. P., Murphy, L. O. & Blenis, J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biol. 7, 591-600 (2005). (Pubitemid 40796982)
15. Whitehurst, A. W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007). (Pubitemid 46582032)
16. Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002). (Pubitemid 34408678)
17. Moffat, J. et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
18. Silva, J. M. et al. Second-generation shRNA libraries covering the mouse and human genomes. Nature Genet. 37, 1281-1288 (2005). (Pubitemid 41568714)
19. Kittler, R. et al. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nature Methods 4, 337-344 (2007). (Pubitemid 46766979)
20. Premsrirut, P. K. et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145, 145-158 (2011).
21. Fellmann, C. et al. Functional identification of optimized RNAi triggers using a massively parallel ensor assay. Mol. Cell 41, 733-746 (2011).
22. Echeverri, C. J. et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nature Methods 3, 777-779 (2006). (Pubitemid 44445821)
23. Seed, B. & Aruffo, A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl Acad. Sci. USA 84, 3365-3369 (1987). (Pubitemid 17085404)
24. Shih, C. & Weinberg, R. A. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29, 161-169 (1982).
25. Lin, H. Y. et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254, 1022-1024 (1991). (Pubitemid 21917435)
26. Temple, G. et al. The completion of the Mammalian Gene Collection (MGC). Genome Res. 19, 2324-2333 (2009).
27. Bechtel, S. et al. The full-ORF clone resource of the German cDNA Consortium. BMC Genomics 8, 399 (2007).
28. Lamesch, P. et al. Human ORFeome 3.1: a resource of human open reading frames covering over 10,000 human genes. Genomics 89, 307-315 (2007). (Pubitemid 46210126)
29. Ota, T. et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature Genet. 36, 40-45 (2004). (Pubitemid 38056206)
30. Park, J. et al. Building a human kinase gene repository: bioinformatics, molecular cloning, and functional validation. Proc. Natl Acad. Sci. USA 102, 8114-8119 (2005). (Pubitemid 40800052)
31. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
32. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nature Methods (in the press).
33. Griffiths-Jones, S. miRBase: the microRNA sequence database. Methods Mol. Biol. 342, 129-138 (2006).
34. Calin, G. A. et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002). (Pubitemid 35403967)
35. Voorhoeve, P. M. et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumours. Cell 124, 1169-1181 (2006).
36. McDermott, U. et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 69, 3937-3946 (2009).
37. McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumour cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
38. Schreiber, S. L. et al. Towards patient-based cancer therapeutics. Nature Biotech. 28, 904-906 (2010).
39. Nielsen, T. E. & Schreiber, S. L. Towards the optimal screening collection: a synthesis strategy. Angew. Chem. Int. Ed. Engl. 47, 48-56 (2008).
40. Stanton, B. Z. et al. A small molecule that binds Hedgehog and blocks its signalling in human cells. Nature Chem. Biol. 5, 154-156 (2009).
41. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009).
42. Zhu, S. et al. A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 4, 416-426 (2009).
43. Wurdak, H. et al. An RNAi screen identifies TRRAP as a regulator of brain tumour-initiating cell differentiation. Cell Stem Cell 6, 37-47 (2010).
44. Schmitz, M. H. et al. Live-cell imaging RNAi screen identifies PP2A-B55α and importin-β1 as key mitotic exit regulators in human cells. Nature Cell Biol. 12, 886-893 (2010).
45. Wheeler, D. B., Carpenter, A. E. & Sabatini, D. M. Cell microarrays and RNA interference chip away at gene function. Nature Genet. 37, S25-S30 (2005). (Pubitemid 40770400)
46. Vegas, A. J., Fuller, J. H. & Koehler, A. N. Small-molecule microarrays as tools in ligand discovery. Chem. Soc. Rev. 37, 1385-1394 (2008).
47. Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007). (Pubitemid 47539306)
48. Hurov, K. E., Cotta-Ramusino, C. & Elledge, S. J. A genetic screen identifies the Triple T complex required for DNA damage signalling and ATM and ATR stability. Genes Dev. 24, 1939-1950 (2010).
49. Smogorzewska, A. et al. A genetic screen identifies FAN1, a Fanconi anaemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol. Cell 39, 36-47 (2010).
50. Paddison, P. J. et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 428, 427-431 (2004). (Pubitemid 38419688)
51. Brummelkamp, T. R. & Bernards, R. New tools for functional mammalian cancer genetics. Nature Rev. Cancer 3, 781-789 (2003). (Pubitemid 37328816)
52. Ngo, V. N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110 (2006).
53. Buchholz, F., Kittler, R., Slabicki, M. & Theis, M. Enzymatically prepared RNAi libraries. Nature Methods 3, 696-700 (2006). (Pubitemid 44275736)
54. Schlabach, M. R. et al. Cancer proliferation gene discovery through functional genomics. Science 319, 620-624 (2008). (Pubitemid 351197064)
55. Luo, B. et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl Acad. Sci. USA 105, 20380-20385 (2008).
56. Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifies tumour suppressors in liver cancer. Cell 135, 852-864 (2008).
57. Bric, A. et al. Functional identification of tumour-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16, 324-335 (2009).
58. Meacham, C. E., Ho, E. E., Dubrovsky, E., Gertler, F. B. & Haemann, M. T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genet. 41, 1133-1137 (2009).
59. Zuber, J. et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nature Biotech. 29, 79-83 (2011).
60. Kittler, R. et al. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nature Cell Biol. 9, 1401-1412 (2007). (Pubitemid 350201753)
61. Cheng, H. et al. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci. Signal. 2, ra35 (2009).
62. Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
63. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004). (Pubitemid 38419689)
64. Westbrook, T. F. et al. A genetic screen for candidate tumour suppressors identifies REST. Cell 121, 837-848 (2005). (Pubitemid 40806416)
65. Kolfschoten, I. G. et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121, 849-858 (2005). (Pubitemid 40806417)
66. Firestein, R. et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature 455, 547-551 (2008).
67. Peeper, D. S. et al. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nature Cell Biol. 4, 148-153 (2002). (Pubitemid 34141481)
68. Gazin, C., Wajapeyee, N., Gobeil, S., Virbasius, C. M. & Green, M. R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449, 1073-1077 (2007). (Pubitemid 350014604)
69. Collins, C. S. et al. A small interfering RNA screen for modulators of tumour cell motility identifies MAP4K4 as a promigratory kinase. Proc. Natl Acad. Sci. USA 103, 3775-3780 (2006). (Pubitemid 43376631)
70. Smolen, G. A. et al. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev. 24, 2654-2665 (2010).
71. Epping, M. T. et al. A functional genetic screen identifies retinoic acid signalling as a target of histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 104, 17777-17782 (2007). (Pubitemid 350210911)
72. O'Connell, B. C. et al. A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability. Mol. Cell 40, 645-657 (2010).
73. Fotheringham, S. et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15, 57-66 (2009).
74. Chen, S. et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 70, 4318-4326 (2010).
75. Eichhorn, P. J. et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68, 9221-9230 (2008).
76. Mullenders, J. et al. Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin. Cancer Res. 15, 5811-5819 (2009).
77. Hahn, C. K. et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16, 281-294 (2009).
78. Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257-263 (2004). (Pubitemid 38282750)
79. Bradner, J. E. et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. Natl Acad. Sci. USA 107, 12617-12622 (2010).
80. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006). (Pubitemid 44497995)
81. Du, J. et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature Biotech. 27, 77-83 (2009).
82. Pujana, M. A. et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nature Genet. 39, 1338-1349 (2007). (Pubitemid 350035000)
83. Wilson, B., Liotta, L. A. & Petricoin, E. Monitoring proteins and protein networks using reverse phase protein arrays. Disease Markers 28, 225-232 (2010).
84. Evangelista, M. et al. Kinome siRNA screen identifies regulators of ciliogenesis and hedgehog signal transduction. Sci. Signal. 1, ra7 (2008).
85. Lam, L. T. et al. Compensatory IKKα activation of classical NF-κB signalling during IKKβ inhibition identified by an RNA interference sensitization screen. Proc. Natl Acad. Sci. USA 105, 20798-20803 (2008).
86. Sheng, Q. et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17, 298-310 (2010).
87. Baldwin, A. et al. Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc. Natl Acad. Sci. USA 105, 16478-16483 (2008).
88. Brummelkamp, T. R., Nijman, S. M., Dirac, A. M. & Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424, 797-801 (2003). (Pubitemid 37021711)
89. Nijman, S. M. et al. The deubiquitinating enzyme USP1 regulates the Fanconi anaemia pathway. Mol. Cell 17, 331-339 (2005). (Pubitemid 40193305)
90. Boehm, J. S. et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079 (2007). (Pubitemid 46891036)
91. Varjosalo, M. et al. Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signalling. Cell 133, 537-548 (2008). (Pubitemid 351622012)
92. Gonzalez-Malerva, L. et al. High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc. Natl Acad. Sci. USA 108, 2058-2063 (2011).
93. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
94. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
95. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and suppression of STK33 in human cancer cells. Cell 137, 821-834 (2009).
96. Vicent, S. et al. Wilms tumour 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J. Clin. Invest. 120, 3940-3952 (2010).
97. Wang, Y. et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 29, 4658-4670 (2010).
98. Baldwin, A. et al. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc. Natl Acad. Sci. USA 107, 12463-12468 (2010).
99. Bommi-Reddy, A. et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc. Natl Acad. Sci. USA 105, 16484-16489 (2008).
100. Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368-1377 (2008). (Pubitemid 351655175)
101. Shaffer, A. L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226-231 (2008). (Pubitemid 351969894)
102. Iorns, E., Lord, C. J. & Ashworth, A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem. J. 417, 361-370 (2009).
103. Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genet. 42, 715-721 (2010).
104. Sawey, E. T. et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347-358 (2011).
105. - syndrome gene by RNA interference screen. Nature 451, 335-339 (2008).
106. Silva, J. M. et al. Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell 137, 1047-1061 (2009).
107. Zender, L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253-1267 (2006). (Pubitemid 43929093)
108. Kim, M. et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125, 1269-1281 (2006). (Pubitemid 43949521)
109. Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
110. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). (Pubitemid 40559005)
111. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
112. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N.Engl. J. Med. 361, 123-134 (2009).
113. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659 (2009).